ElyssaMed® will develop the first therapeutic treatment for clinical use comprising several antigenic peptides (epitopes) derived from CTPP and selective for non-small-cell lung cancer, combined with an already marketed vaccine adjuvant.
This product once administered to lung cancer patients, will amplify the patients' specific immune responses against tumor cells expressing the antigen CTPP and lead to their destruction.
Company Details
- Employees
- 2
- Founded
- -
- Address
- Paris
- co****@****med.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- elyssamed.com
- HQ
- Paris
Elyssamed Sas Questions
Elyssamed Sas's website is elyssamed.com
Elyssamed Sas's LinkedIn profile is https://fr.linkedin.com/company/elyssamed-sas
Elyssamed Sas has
2 employees.
View email and phone details for 2
employees at Elyssamed Sas.
Elyssamed Sas's industry is
Biotechnology Research
Elyssamed Sas's top competitors are
Gliocure,
Bcell Design,
Biomunex Pharmaceuticals,
Affilogic,
Invectys,
Imcheck Therapeutics,
Theravectys,
Nanobiotix,
Telomium,
Stimunity.
Elyssamed Sas's support email address is contact@elyssamed.com
Elyssamed Sas's categories are Biotechnology Research
Elyssamed Sas's founding year is 2015
